Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
Roberts HJ, Ji S, Picca A, Sanson M, Garcia M, Snuderl M, Schüller U, Picart T, Ducray F, Green AL, Nakano Y, Sturm D, Abdullaev Z, Aldape K, Dang D, Kumar-Sinha C, Wu YM, Robinson D, Vo JN, Chinnaiyan AM, Cartaxo R, Upadhyaya SA, Mody R, Chiang J, Baker S, Solomon D, Venneti S, Pratt D, Waszak SM, Koschmann C. Roberts HJ, et al. Among authors: picca a. Acta Neuropathol. 2023 Dec;146(6):849-852. doi: 10.1007/s00401-023-02640-7. Epub 2023 Oct 18. Acta Neuropathol. 2023. PMID: 37851269 Free PMC article. No abstract available.
The clinical use of IDH1 and IDH2 mutations in gliomas.
Picca A, Berzero G, Di Stefano AL, Sanson M. Picca A, et al. Expert Rev Mol Diagn. 2018 Dec;18(12):1041-1051. doi: 10.1080/14737159.2018.1548935. Epub 2018 Nov 29. Expert Rev Mol Diagn. 2018. PMID: 30427756 Free article. Review.
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L, Ajlil Y, Tauziède-Espariat A, Kergrohen T, Puiseux C, Riffaud L, Blouin P, Bertozzi AI, Leblond P, Blomgren K, Froelich S, Picca A, Touat M, Sanson M, Beccaria K, Blauwblomme T, Dangouloff-Ros V, Boddaert N, Varlet P, Debily MA, Grill J, Castel D. Auffret L, et al. Among authors: picca a. Acta Neuropathol. 2023 Dec 8;147(1):2. doi: 10.1007/s00401-023-02651-4. Acta Neuropathol. 2023. PMID: 38066305 Free PMC article.
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network. Picca A, et al. Eur J Cancer. 2024 May;202:114034. doi: 10.1016/j.ejca.2024.114034. Epub 2024 Mar 22. Eur J Cancer. 2024. PMID: 38537315 Clinical Trial.
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F, Di Stefano AL, Meyronet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D, Maurage CA, Uro-Coste E, Lasorella A, Iavarone A, Sanson M, Mokhtari K. Bielle F, et al. Among authors: picca a. Brain Pathol. 2018 Sep;28(5):674-683. doi: 10.1111/bpa.12563. Epub 2017 Nov 21. Brain Pathol. 2018. PMID: 28976058 Free PMC article.
225 results